Three years after failing in Alzheimer’s, Merck is investing more in neuroscience
Back 2017, the decisive failure of a Merck drug called verubecestat helped bring about the end of an entire wing of Alzheimer’s disease research. Now, Merck is gradually building back a neuroscience pipeline, partnering with a startup on some early-stage projects.
As STAT’s Adam Feuerstein reports, Merck signed a deal with Yumanity Therapeutics in hopes of finding novel treatments for amyotrophic lateral sclerosis, or ALS, and frontotemporal lobar dementia, a group of related conditions resulting from the degeneration of brain cells.
Yumanity, founded in 2014 by biotech entrepreneur Tony Coles, is building on the discoveries of Susan Lindquist, a well-known researcher and National Medal of Science recipient who used yeast as a model organism to study neurodegenerative diseases caused by misfolded proteins.
Read more.
As STAT’s Adam Feuerstein reports, Merck signed a deal with Yumanity Therapeutics in hopes of finding novel treatments for amyotrophic lateral sclerosis, or ALS, and frontotemporal lobar dementia, a group of related conditions resulting from the degeneration of brain cells.
Yumanity, founded in 2014 by biotech entrepreneur Tony Coles, is building on the discoveries of Susan Lindquist, a well-known researcher and National Medal of Science recipient who used yeast as a model organism to study neurodegenerative diseases caused by misfolded proteins.
Read more.
.png)
No hay comentarios:
Publicar un comentario